Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 22, 2005. The document serves as a notification of major interests in shares and changes in directors' interests, rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholding notifications and trust transactions.
Material Changes
- Barclays plc Shareholding: Barclays plc's total holding in GlaxoSmithKline plc fluctuated during the reporting period. On April 14, 2005, the holding increased from 3.91% to 4.14% of issued share capital (excluding treasury shares). By April 19, 2005, the holding decreased from 4.14% back to 3.9%.
- Total Share Count: The total number of shares held by Barclays entities remained constant at 228,479,243 across both notification dates, with internal reallocations between subsidiaries.
- Directors' Interests: The GlaxoSmithKline Employee Trust transferred 7,141 ordinary shares to participants in the Performance Share Plan on April 20, 2005, and 1,638 shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on April 21, 2005.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is a regulatory disclosure of ownership changes.
Investor Verification Checklist
- Verify the exact percentage of issued share capital held by Barclays plc as of the most recent trading day, noting the fluctuation between 3.9% and 4.14%.
- Confirm the internal reallocation of shares among Barclays subsidiaries (e.g., Barclays Global Investors Ltd, Barclays Capital Securities Ltd) to understand the composition of the 228,479,243 total holding.
- Review the impact of the 8,779 shares transferred from the GSK Trust to employee plans on the company's treasury share count.
- Check subsequent filings for any further changes in major shareholder interests or director holdings.